Triple or dual antithrombotic therapy post‐percutaneous coronary intervention: Which one is better?

Abstract

Dual antiplatelet therapy is the usual standard of care post-percutaneous coronary intervention (PCI)1 . Nevertheless, in patients who are receiving concurrent systemic anticoagulation, there is a growing concern that the bleeding risk with the resulting triple antithrombotic therapy (TAT) may outweigh any potential benefits. This is further supported by the recognition that bleeding events post-PCI are associated with worse overall outcomes.2 This article is protected by copyright. All rights reserved.